The state of emergency imposed in August had allowed the local authorities to curb movement in the worst-hit areas of the country, including the capital Monrovia.
The lifting of the emergency comes after the World Health Organization (WHO) said œthere is some evidence that case incidence is no longer increasing nationally in Guinea and Liberia.
However, some reports suggest that new fresh hotspots have emerged in Liberia, the Associated Press reports.
˜Hope for patientsIn a separate development, MSF announced the new clinical trials: two in Guinea and another one in an unconfirmed location.
One trial will involve using the blood of recovered Ebola patients to treat sick people in the Guinean capital Conakry.
œThis is an unprecedented international partnership which represents hope for patients to finally get a real treatment, said MSF spokeswoman Dr Annick Antierens.
About 400 people will take part in the trials, and they will be extended to other centres if the early results “ expected in February 2015 “ are promising.
The WHO announced in September that experimental treatments and vaccines for Ebola should be fast-tracked.
Two experimental vaccines, produced by GlaxoSmithKline (GSK) and the Public Health Agency of Canada, have already been fast-tracked into safety trials.
The GSK vaccine is being tested in Mali, the UK and the US. Research on the Canadian vaccine is also under way in the US.
Cumulative deaths up to 11 November
*Figures are occasionally revised down as suspect or probable cases are found to be unrelated to Ebola. Figures for Liberia, Sierra Leone and Guinea up to 9 November, while those for Mali, Nigeria and the US up to 11 November.